Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million
Oruka Therapeutics jumped to secure $500 million through stock and pre-funded warrants Monday, following a spike in its shares after interim results from its investigational psoriasis treatment. The surge also sparked new comparisons to big-name drugs from AbbVie and UCB.